Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes Sells 3,000 Shares

Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares in the company, valued at $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Hykes also recently made the following trade(s):

• On Tuesday, October 29th, Andrew Hykes sold 3,000 shares of Inari Medical stock. The stock was sold at an average price of $50.00, for a total value of $150,000.00.

Inari Medical Stock Up 1.9 %

NASDAQ NARI traded up $1.04 during trading hours on Friday, hitting $55.45. 1,874,948 shares of the company were exchanged, compared to its average volume of 998,000. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $66.61. The stock has a 50-day moving average price of $49.84 and a 200 day moving average price of $48.13. The stock has a market cap of $3.25 billion, a PE ratio of -41.07 and a beta of 0.97.

Wall Street Analysts Forecast Growth

NARI has been the topic of several recent analyst reports. Truist Financial lifted their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Canaccord Genuity Group increased their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. Robert W. Baird raised their price objective on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, October 29th. Finally, Leerink Partnrs upgraded Inari Medical to a “hold” rating in a research report on Tuesday, September 3rd. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $61.80.

Hedge Funds Weigh In On Inari Medical

Several large investors have recently modified their holdings of NARI. Franklin Resources Inc. boosted its stake in Inari Medical by 2.2% during the third quarter. Franklin Resources Inc. now owns 223,810 shares of the company’s stock worth $9,445,000 after buying an additional 4,899 shares during the period. Barclays PLC lifted its holdings in shares of Inari Medical by 9.7% in the 3rd quarter. Barclays PLC now owns 288,079 shares of the company’s stock worth $11,881,000 after acquiring an additional 25,365 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its stake in shares of Inari Medical by 316.7% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 44,318 shares of the company’s stock worth $1,828,000 after purchasing an additional 33,682 shares during the period. Jane Street Group LLC grew its holdings in Inari Medical by 32.4% during the 3rd quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock valued at $3,927,000 after purchasing an additional 23,286 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new stake in Inari Medical in the 3rd quarter worth about $9,008,000. Institutional investors own 90.98% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.